These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31351062)

  • 1. Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses.
    Gentry-Maharaj A; Burnell M; Dilley J; Ryan A; Karpinskyj C; Gunu R; Mallett S; Deeks J; Campbell S; Jacobs I; Sundar S; Menon U
    Am J Obstet Gynecol; 2020 Jan; 222(1):56.e1-56.e17. PubMed ID: 31351062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrasound Features Improve Diagnostic Performance of Ovarian Cancer Predictors in Distinguishing Benign and Malignant Ovarian Tumors.
    Chen YN; Ma F; Zhang YD; Chen L; Li CY; Gong SP
    Curr Med Sci; 2020 Feb; 40(1):184-191. PubMed ID: 32166682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
    Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
    Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.
    Menon U; Gentry-Maharaj A; Burnell M; Ryan A; Kalsi JK; Singh N; Dawnay A; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Parmar M; Jacobs IJ
    Health Technol Assess; 2023 May; ():1-81. PubMed ID: 37183782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients.
    Braicu EI; Krause CL; Torsten U; Mecke H; Richter R; Hellmeyer L; Lanowska M; Müller B; Koch E; Boenneß-Zaloum J; Ames K; Chekerov R; Hasenbein K; Zimmermann M; Mangler M; Chen F; Tauber R; Sehouli J
    BMC Cancer; 2022 Jul; 22(1):831. PubMed ID: 35907794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Menon U; Gentry-Maharaj A; Hallett R; Ryan A; Burnell M; Sharma A; Lewis S; Davies S; Philpott S; Lopes A; Godfrey K; Oram D; Herod J; Williamson K; Seif MW; Scott I; Mould T; Woolas R; Murdoch J; Dobbs S; Amso NN; Leeson S; Cruickshank D; McGuire A; Campbell S; Fallowfield L; Singh N; Dawnay A; Skates SJ; Parmar M; Jacobs I
    Lancet Oncol; 2009 Apr; 10(4):327-40. PubMed ID: 19282241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Performance of F-18 FDG PET/CT Compared with CA125, HE4, and ROMA for Epithelial Ovarian Cancer.
    Lee SS; Park JS; Lee KB; Jeong DH; Byun JM; Lee SM
    Asian Pac J Cancer Prev; 2021 Apr; 22(4):1123-1127. PubMed ID: 33906304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of CA125, human epididymis protein 4 (HE4), risk of ovarian malignancy algorithm (ROMA), risk of malignancy index (RMI) and subjective assessment (SA) in preoperative diagnosing of ovarian tumors.
    Janas L; Stachowiak G; Glowacka E; Piwowarczyk I; Kajdos M; Soja M; Masternak M; Nowak M
    Ginekol Pol; 2024; 95(5):321-327. PubMed ID: 36597746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses.
    Hada A; Han LP; Chen Y; Hu QH; Yuan Y; Liu L
    J Ovarian Res; 2020 Apr; 13(1):46. PubMed ID: 32334618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
    Ahmed AA; Abdou AM
    Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].
    Shipeng G; Yongning C; Yadi Z; Chanyuan LI; Qifan J
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Dec; 39(12):1393-1401. PubMed ID: 31907150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.
    Zhang L; Chen Y; Wang K
    Curr Probl Cancer; 2019 Apr; 43(2):135-144. PubMed ID: 30017407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic accuracy of human epididymis protein 4 (HE4) for discriminating between benign and malignant pelvic masses: a systematic review and meta-analysis.
    Olsen M; Lof P; Stiekema A; van den Broek D; Wilthagen EA; Bossuyt PM; Lok CAR
    Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1788-1799. PubMed ID: 34212386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS).
    Sharma A; Apostolidou S; Burnell M; Campbell S; Habib M; Gentry-Maharaj A; Amso N; Seif MW; Fletcher G; Singh N; Benjamin E; Brunell C; Turner G; Rangar R; Godfrey K; Oram D; Herod J; Williamson K; Jenkins H; Mould T; Woolas R; Murdoch J; Dobbs S; Leeson S; Cruickshank D; Fourkala EO; Ryan A; Parmar M; Jacobs I; Menon U
    Ultrasound Obstet Gynecol; 2012 Sep; 40(3):338-44. PubMed ID: 22911637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HE4 might be a more useful tumor biomarker to detect malignancy in patients with ovarian endometrioma when malignancy is suspected.
    Rius M; Fusté P; Ros C; Martínez-Zamora Á; deGuirior C; Gracia M; Mension E; Carmona F
    J Int Med Res; 2021 Sep; 49(9):3000605211047701. PubMed ID: 34590878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
    Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
    Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
    PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.
    Li F; Tie R; Chang K; Wang F; Deng S; Lu W; Yu L; Chen M
    BMC Cancer; 2012 Jun; 12():258. PubMed ID: 22712526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
    Wang Z; Tao X; Ying C
    Dis Markers; 2019; 2019():6241743. PubMed ID: 31737130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.